Meredith Y Smith

Summary

Affiliation: Purdue Pharma
Country: USA

Publications

  1. ncbi The impact of PTSD on pain experience in persons with HIV/AIDS
    Meredith Y Smith
    Purdue Pharma, L P, One Stamford Forum, Stamford, CT 06901 3431, USA
    Pain 98:9-17. 2002
  2. ncbi Patient-physician communication in the context of persistent pain: validation of a modified version of the patients' Perceived Involvement in Care Scale
    Meredith Y Smith
    Program for Cancer Prevention and Control, Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY, USA
    J Pain Symptom Manage 32:71-81. 2006
  3. doi Detecting signals of opioid analgesic abuse: application of a spatial mixed effect poisson regression model using data from a network of poison control centers
    Meredith Y Smith
    Purdue Pharma LP, Stamford, CT, USA
    Pharmacoepidemiol Drug Saf 17:1050-9. 2008
  4. ncbi Correlates of nonmedical use of hydromorphone and hydrocodone:results from a national household survey
    Meredith Y Smith
    Purdue Pharma L P, One Stamford Forum, Stamford, CT 06901 3431, USA
    J Pain Palliat Care Pharmacother 21:5-17. 2007
  5. ncbi Abuse of buprenorphine in the United States: 2003-2005
    Meredith Y Smith
    Risk Management and Health Policy, Purdue Pharma L P, Stamford, CT 06901 3431, USA
    J Addict Dis 26:107-11. 2007
  6. ncbi Determining the cost-effectiveness of a computer-based smoking cessation intervention in primary care
    Meredith Y Smith
    Purdue Pharma, Stamford, CT 06901 3431, USA
    Manag Care 16:48-55. 2007
  7. ncbi Quantifying morbidity associated with the abuse and misuse of opioid analgesics: a comparison of two approaches
    Meredith Y Smith
    Purdue Pharma L P, One Stamford Forum, Stamford, Connecticut 06901 3431, USA
    Clin Toxicol (Phila) 45:23-30. 2007
  8. ncbi Clinician validation of Poison Control Center (PCC) intentional exposure cases involving prescription opioids
    Meredith Y Smith
    Purdue Pharma L P, Stamford, Connecticut 06901 3431, USA
    Am J Drug Alcohol Abuse 32:465-78. 2006
  9. ncbi Nonmedical use and abuse of scheduled medications prescribed for pain, pain-related symptoms, and psychiatric disorders: patterns, user characteristics, and management options
    Meredith Y Smith
    Purdue Pharma, L P, One Stamford Forum, Stamford, CT 06901, USA
    Curr Psychiatry Rep 7:337-43. 2005
  10. doi Impact of a brief intervention on patient communication and barriers to pain management: results from a randomized controlled trial
    Meredith Y Smith
    Cancer Prevention and Control Division, Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY, USA
    Patient Educ Couns 81:79-86. 2010

Detail Information

Publications17

  1. ncbi The impact of PTSD on pain experience in persons with HIV/AIDS
    Meredith Y Smith
    Purdue Pharma, L P, One Stamford Forum, Stamford, CT 06901 3431, USA
    Pain 98:9-17. 2002
    ..e., mood, relations with other people, enjoyment of life) over time than those who did not meet the diagnostic criteria. Possible explanations for these findings are discussed along with implications for clinical care...
  2. ncbi Patient-physician communication in the context of persistent pain: validation of a modified version of the patients' Perceived Involvement in Care Scale
    Meredith Y Smith
    Program for Cancer Prevention and Control, Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY, USA
    J Pain Symptom Manage 32:71-81. 2006
    ..The M-PICS is a reliable and valid measure of perceived patient-provider communication in the context of persistent pain...
  3. doi Detecting signals of opioid analgesic abuse: application of a spatial mixed effect poisson regression model using data from a network of poison control centers
    Meredith Y Smith
    Purdue Pharma LP, Stamford, CT, USA
    Pharmacoepidemiol Drug Saf 17:1050-9. 2008
    ..To assist pharmacovigilance efforts, we developed a methodology for detecting geo-specific "signals" of potential outbreaks of prescription drug abuse by 3-digit ZIP (3DZ) code...
  4. ncbi Correlates of nonmedical use of hydromorphone and hydrocodone:results from a national household survey
    Meredith Y Smith
    Purdue Pharma L P, One Stamford Forum, Stamford, CT 06901 3431, USA
    J Pain Palliat Care Pharmacother 21:5-17. 2007
    ..Nonmedical Dilaudid users were at higher risk for engaging in more serious substance abuse-related behaviors than those who reported lifetime nonmedical use of hydrocodone combination products...
  5. ncbi Abuse of buprenorphine in the United States: 2003-2005
    Meredith Y Smith
    Risk Management and Health Policy, Purdue Pharma L P, Stamford, CT 06901 3431, USA
    J Addict Dis 26:107-11. 2007
    ..08 (SD +/- 0.09) for Subutex, and 0.16 (SD +/- 0.08) for Suboxone. Findings suggest that these sublingual buprenorphine formulations have a low rate of abuse based on toxico-surveillance data...
  6. ncbi Determining the cost-effectiveness of a computer-based smoking cessation intervention in primary care
    Meredith Y Smith
    Purdue Pharma, Stamford, CT 06901 3431, USA
    Manag Care 16:48-55. 2007
    ..To evaluate the incremental effectiveness and cost-effectiveness of a staged-based, computerized smoking cessation intervention relative to standard care in an urban managed care network of primary care physicians...
  7. ncbi Quantifying morbidity associated with the abuse and misuse of opioid analgesics: a comparison of two approaches
    Meredith Y Smith
    Purdue Pharma L P, One Stamford Forum, Stamford, Connecticut 06901 3431, USA
    Clin Toxicol (Phila) 45:23-30. 2007
    ..Due to the rising nonmedical use of opioid analgesics, methods are needed to quantify the associated health-related consequences...
  8. ncbi Clinician validation of Poison Control Center (PCC) intentional exposure cases involving prescription opioids
    Meredith Y Smith
    Purdue Pharma L P, Stamford, Connecticut 06901 3431, USA
    Am J Drug Alcohol Abuse 32:465-78. 2006
    ..Interrater reliability among clinicians was good (weighted kappa range: 0.56-0.68). Results demonstrate the degree of compatibility between PCC and standard nosologic classifications...
  9. ncbi Nonmedical use and abuse of scheduled medications prescribed for pain, pain-related symptoms, and psychiatric disorders: patterns, user characteristics, and management options
    Meredith Y Smith
    Purdue Pharma, L P, One Stamford Forum, Stamford, CT 06901, USA
    Curr Psychiatry Rep 7:337-43. 2005
    ..Sources of diversion are enumerated, and options for minimizing the abuse liability associated with these medications are described...
  10. doi Impact of a brief intervention on patient communication and barriers to pain management: results from a randomized controlled trial
    Meredith Y Smith
    Cancer Prevention and Control Division, Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY, USA
    Patient Educ Couns 81:79-86. 2010
    ....
  11. pmc Self-efficacy for coping with cancer in a multiethnic sample of breast cancer patients: associations with barriers to pain management and distress
    Catherine E Mosher
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
    Clin J Pain 26:227-34. 2010
    ..The extent to which ethnicity (Black, Latina, or White), language (English or Spanish), and level of education and income predicted these variables was also assessed...
  12. ncbi Risk identification, risk assessment, and risk management of abusable drug formulations
    Curtis Wright
    Risk Management and Health Policy, Purdue Pharma L P, One Stamford Forum, Stamford, CT 06901 3431, USA
    Drug Alcohol Depend 83:S68-76. 2006
    ....
  13. ncbi Association between non-medical and prescriptive usage of opioids
    Nabarun Dasgupta
    Risk Management and Health Policy, Purdue Pharma L P, One Stamford Forum, Stamford, CT 06901 3431, USA
    Drug Alcohol Depend 82:135-42. 2006
    ..9791) with the reported morbidity for prescription analgesics as a class, as measured in the DAWN system. These data suggest that non-medical use of opioids is predictable based on potency and extent of prescriptive use...
  14. doi RxPATROL: a Web-based tool for combating pharmacy theft
    Meredith Y Smith
    Risk Management and Health Policy, Purdue Pharma L P, Stamford, CT, USA
    J Am Pharm Assoc (2003) 49:599-603. 2009
    ....
  15. ncbi Reducing opioid. analgesic abuse: models for successful collaboration among government, industry and other key stakeholders
    Meredith Y Smith
    Drug Alcohol Depend 95:177-81. 2008
  16. ncbi The validity and utility of the BPI interference measures for evaluating the impact of osteoarthritic pain
    Valerie S L Williams
    RTI Health Solutions, 3040 Cornwallis Road, PO Box 12194, Research Triangle Park, NC 27709, USA
    J Pain Symptom Manage 31:48-57. 2006
    ....
  17. ncbi Acceptable, manageable, and tolerable days: patient daily goals for medication management of persistent pain
    Diane C Zelman
    California School of Professional Psychology Alliant International University, San Francisco, California 94133 1221, USA
    J Pain Symptom Manage 28:474-87. 2004
    ..Study findings identify a novel construct that can inform development of an outcome for evaluating the effectiveness of different pharmacotherapies for pain management...